124 related articles for article (PubMed ID: 10554836)
1. Weekly intermittent 2-CdA is less toxic and equally efficacious when compared to continuous infusion in hairy cell leukaemia.
Chacko J; Murphy C; Duggan C; O'Briain DS; Browne PV; McCann SR
Br J Haematol; 1999 Jun; 105(4):1145-6. PubMed ID: 10554836
[No Abstract] [Full Text] [Related]
2. Hairy-cell leukaemia: first-line treatment with cladribine or pentostatin.
Prescrire Int; 2006 Aug; 15(84):143-4. PubMed ID: 16989031
[TBL] [Abstract][Full Text] [Related]
3. Successful induction of long-term remission using rituximab in a patient with refractory hairy cell leukemia-Japanese variant.
Imamura T; Ohtsuka E; Ogata M; Oka F; Kashima K; Kikuchi H; Nasu M
Int J Hematol; 2004 Dec; 80(5):432-4. PubMed ID: 15646655
[TBL] [Abstract][Full Text] [Related]
4. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine).
Füreder W; Weltermann A; Chott A; Gisslinger H; Valent P; Jäger U; Geissler K; Lechner K
Wien Klin Wochenschr; 1999 Dec; 111(24):1027-30. PubMed ID: 10677889
[TBL] [Abstract][Full Text] [Related]
5. Antibiotic exposure is associated with cutaneous adverse events in hairy cell leukemia patients treated with purine analogues.
Wang RF; Li D; Kuehn GJ; Andritsos LA; Grever MR; Kaffenberger BH
J Am Acad Dermatol; 2019 Jun; 80(6):1762-1764. PubMed ID: 30205132
[No Abstract] [Full Text] [Related]
6. Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): a National Cancer Institute of Canada study.
Johnston JB; Eisenhauer E; Wainman N; Corbett WE; Zaentz SD; Daeninck PJ
Semin Oncol; 2000 Apr; 27(2 Suppl 5):32-6. PubMed ID: 10877049
[TBL] [Abstract][Full Text] [Related]
7. Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial.
Robak T; Jamroziak K; Gora-Tybor J; Blonski JZ; Kasznicki M; Dwilewicz-Trojaczek J; Wiater E; Zdunczyk A; Dybowicz J; Dmoszynska A; Wojtaszko M; Zdziarska B; Calbecka M; Kostyra A; Hellmann A; Lewandowski K; Stella-Holowiecka B; Sulek K; Gawronski K; Skotnicki AB; Nowak W; Zawilska K; Molendowicz-Portala L; Kloczko J; Sokolowski J; Warzocha K; Seferynska I; Ceglarek B; Konopka L
Blood; 2007 May; 109(9):3672-5. PubMed ID: 17209059
[TBL] [Abstract][Full Text] [Related]
8. Five day intermittent vs seven day continuous 2-chlorodeoxyadenosine infusion for the treatment of hairy cell leukemia. A study by Italian Group for the Hairy Cell Leukemia.
Damasio EE; Resegotti L; Masoudi B; Bruni R; Cerri R; Isaza A; Clavio M; Risso M; Rossi E; Spriano M; Truini M
Recenti Prog Med; 1998 Feb; 89(2):68-73. PubMed ID: 9558908
[TBL] [Abstract][Full Text] [Related]
9. Cladribine in the treatment of hairy-cell leukaemia.
Goodman GR; Beutler E; Saven A
Best Pract Res Clin Haematol; 2003 Mar; 16(1):101-16. PubMed ID: 12670469
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of patients with hairy cell leukaemia after treatment with pentostatin or cladribine.
Dearden CE; Matutes E; Hilditch BL; Swansbury GJ; Catovsky D
Br J Haematol; 1999 Aug; 106(2):515-9. PubMed ID: 10460614
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis.
Else M; Dearden CE; Matutes E; Garcia-Talavera J; Rohatiner AZ; Johnson SA; O'Connor NT; Haynes A; Osuji N; Forconi F; Lauria F; Catovsky D
Br J Haematol; 2009 Jun; 145(6):733-40. PubMed ID: 19344416
[TBL] [Abstract][Full Text] [Related]
12. 2-chlorodeoxyadenosine (2-CdA) in 2-hour versus 24-hour intravenous infusion in the treatment of patients with hairy cell leukemia.
Robak T; Błasińska-Morawiec M; Krykowski E; Hansz J; Komarnicki M; Kazimierczak M; Konopka L; Maj S; Hellmann A; Zaucha JM; Urasiński L; Zdziarska B; Kotlarek-Haus S; Usnarska-Zubkiewicz L; Kuratowska Z; Dwilewicz-Trojaczek J; Hołowiecki J; Krawczyk-Kulis M; Grieb P
Leuk Lymphoma; 1996 Jun; 22(1-2):107-11. PubMed ID: 8724536
[TBL] [Abstract][Full Text] [Related]
13. Phase II clinical study of cladribine in the treatment of hairy cell leukemia.
Machii T; Chou T; Suzuki M; Ohe Y; Katagiri S; Kitano EK; Kitano K; Fujiyama Y; Izumi T; Shimazaki C; Nanba K; Ohashi Y; Kitani T;
Int J Hematol; 2005 Oct; 82(3):230-5. PubMed ID: 16207596
[TBL] [Abstract][Full Text] [Related]
14. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications.
Lauria F; Bocchia M; Marotta G; Raspadori D; Zinzani PL; Rondelli D
Haematologica; 1999 Jan; 84(1):22-5. PubMed ID: 10091389
[TBL] [Abstract][Full Text] [Related]
15. Treatment of hairy cell leukemia-variant with cladribine.
Tetreault SA; Robbins BA; Saven A
Leuk Lymphoma; 1999 Oct; 35(3-4):347-54. PubMed ID: 10706459
[TBL] [Abstract][Full Text] [Related]
16. Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence.
Else M; Dearden CE; Matutes E; Forconi F; Lauria F; Ahmad H; Kelly S; Liyanage A; Ratnayake V; Shankari J; Whalley I; Catovsky D
Leuk Lymphoma; 2011 Jun; 52 Suppl 2():75-8. PubMed ID: 21504288
[TBL] [Abstract][Full Text] [Related]
17. Nucleoside analogues in the therapy of Langerhans cell histiocytosis: a survey of members of the histiocyte society and review of the literature.
Weitzman S; Wayne AS; Arceci R; Lipton JM; Whitlock JA
Med Pediatr Oncol; 1999 Nov; 33(5):476-81. PubMed ID: 10531572
[TBL] [Abstract][Full Text] [Related]
18. [Subcutaneous therapy of hairy cell leukemia with 2-chlorodeoxyadenosine].
Nielsen OJ; Hippe E; Priø TK; Juliusson G
Ugeskr Laeger; 1994 Apr; 156(16):2407-9. PubMed ID: 7912015
[TBL] [Abstract][Full Text] [Related]
19. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine.
Jehn U; Bartl R; Dietzfelbinger H; Haferlach T; Heinemann V
Leukemia; 2004 Sep; 18(9):1476-81. PubMed ID: 15229616
[TBL] [Abstract][Full Text] [Related]
20. [Successful treatment with cladribine for hypoplastic hairy cell leukemia after long-term neutropenia].
Sakai R; Yamazaki E; Sakamoto H; Kanamori H; Ishigatsubo Y
Rinsho Ketsueki; 2005 Nov; 46(11):1187-90. PubMed ID: 16440801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
